- Investigator
- Francesco Franchi
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Research at a glance
Top areas of exploration
- Platelet Aggregation Inhibitors , 79 publications
- Percutaneous Coronary Intervention , 47 publications
- Purinergic P2Y Receptor Antagonists , 41 publications
- Clopidogrel , 35 publications
Research activity
Active clinical trials
My publications
Filter publications
128 publications
2022
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study.
Journal of thrombosis and thrombolysis
PubMed • Publisher's site2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
European heart journal. Cardiovascular pharmacotherapy
PubMed • Publisher's site2022
Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Pharmacogenomics
PubMed • Publisher's site2022
Reply: The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?
JACC. Cardiovascular interventions
PubMed • Publisher's site2022
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
European heart journal. Cardiovascular pharmacotherapy
PubMed • Publisher's site